These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15758287)

  • 1. Clinical effects of calcimimetics in hyperparathyroidism.
    Peacock M
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):414-5. PubMed ID: 15758287
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcimimetics--fooling the calcium receptor.
    Ritz E
    Pediatr Nephrol; 2005 Jan; 20(1):15-8. PubMed ID: 15517414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary--calcium receptors: potential targets for novel treatments for skeletal disease.
    Nemeth EF
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):416-7. PubMed ID: 15758288
    [No Abstract]   [Full Text] [Related]  

  • 4. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)].
    Nagano N; Kawata T; Wada M
    Nihon Yakurigaku Zasshi; 2008 Nov; 132(5):301-8. PubMed ID: 19008642
    [No Abstract]   [Full Text] [Related]  

  • 7. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient.
    Komaba H; Shin J; Fukagawa M
    Nephrol Dial Transplant; 2010 Feb; 25(2):638-41. PubMed ID: 19892751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2008 Jan; 18(1):20-6. PubMed ID: 18175867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality.
    Schmitt CP; Odenwald T; Ritz E
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S78-80. PubMed ID: 16565253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism.
    Cunningham J
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V9-14. PubMed ID: 15284354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation and action of the calcium-sensing receptor.
    Drüeke TB
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V20-26. PubMed ID: 15284356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies.
    Drueke T; Martin D; Rodriguez M
    Nephrol Dial Transplant; 2007 Jul; 22(7):1828-39. PubMed ID: 17449493
    [No Abstract]   [Full Text] [Related]  

  • 15. [Calcimimetics as a new chance for effective treatment of calcium metabolism disturbances].
    Nowak Z; Laudański K
    Pol Merkur Lekarski; 2002 Nov; 13(77):424-7. PubMed ID: 12621766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Induced change in the function of parathyroid activity].
    Kaiser W
    Endokrinologie; 1970; 55(5):383-91. PubMed ID: 5439571
    [No Abstract]   [Full Text] [Related]  

  • 19. Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism?
    Fukagawa M
    Nat Clin Pract Nephrol; 2006 May; 2(5):248-9. PubMed ID: 16932435
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary hyperparathyroidism (PHP) revisited.
    Kleeman CR; Salehmoghaddam S; Hertz G
    Adv Exp Med Biol; 1986; 208():17-45. PubMed ID: 3551527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.